Laparoscopic Radical Cystoprostatectomy: Our Experience in a Consecutive Series of 10 Patients With a 3 Years Follow-Up

Simonato, Alchiede; Gregori, Andrea; Lissiani, A.; Bozzola, A.; Galli, Stefano; Gaboardi, F.

doi:10.1016/s0022-5347(06)00184-4

Cited by 11 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stein et al reported in his study of 1054 patients undergoing ORC that most deaths from bladder cancer occur within the first 3 years of cystectomy, after which very few patients die as a result of their disease. 17 In our LRC group, among the 19 patients who were followed-up for more than 3 years, six had recurrence and three (15.8%) patients died as a result of bladder cancer.…”

mentioning

confidence: 70%

“…Three patients developed metastatic disease (two bone metastases and one liver and lung metastasis). Simonato et al 17 published data for 10 patients who underwent LRC with a 3-year follow-up, for whom the disease-specific survival rate was 60%. Recurrences occurred after 7, 14, 16, and 28 months and these patients died at 20, 18, 22, and 31 months, respectively.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Laparoscopic versus open radical cystectomy for the management of bladder cancer: Mid‐term oncological outcome

Kim

et al. 2009

Int J of Urology

View full text Add to dashboard Cite

Results: Median follow-up of the LRC group was 21 months (3-56 months). Pathological stage or grade was similar in the two groups. There was no significant difference between the LRC and ORC groups in terms of 3-year overall (64.2% vs 72.6%, respectively; P = 0.682), cancer-specific (73.0% vs 75.3%, respectively; P = 0.951), and recurrence-free survival (70.5% vs 72.5%, respectively; P = 0.715) rates. In a subgroup analysis according to stage, there was also no significant difference in the 3-year disease-specific survival after LRC or ORC for organ-confined (pT1 and pT2; 85.7% vs 83.9%, respectively; P = 0.256) or extravesical disease (pT3 and pT4; 73.3% vs 63.8%, respectively; P = 0.825). Conclusion: These findings suggest that LRC provides mid-term oncological outcomes similar to those of ORC in the management of bladder cancer.

show abstract

mentioning

confidence: 70%

mentioning

confidence: 99%

Laparoscopic versus open radical cystectomy for the management of bladder cancer: Mid‐term oncological outcome

Kim

et al. 2009

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…Two patients (5%) with a final pathology stage of pT3a and pT4a had focally positive surgical margins in the bladder specimen. The mean (range) bladder specimen weight was 1 3 9 296 (225-400) g. A limited lymphadenectomy was used in the initial 11 patients (29%), with a median yield of 6 (2-15) nodes; an extended pelvic lymphadenectomy was used in the subsequent 26 patients (70%), with an increased median yield of 21 (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24) nodes. Overall, the median number of lymph nodes excised was 14 (2-24).…”

Section: Resultsmentioning

confidence: 99%

“…Simonato et al [14] . reported 10 patients having a mean of 2.5 years of follow-up, with five alive with no evidence of disease; four died from metastatic disease and one from unrelated causes.…”

Section: Discussionmentioning

confidence: 98%

Laparoscopic radical cystectomy for cancer: oncological outcomes at up to 5 years

2007

View full text Add to dashboard Cite

OBJECTIVETo report the oncological outcomes at ≤ 5 years after laparoscopic radical cystectomy (LRC), as open RC is the reference standard treatment for muscle-invasive bladder cancer, but interest in LRC is increasing at selected centres worldwide and as yet there are no long-term follow-up data. PATIENTS AND METHODSBetween December 1999 and January 2005, 37 patients (mean age 66 years) had LRC with urinary diversion for invasive bladder cancer; 26 patients (70%) also had an extended pelvic lymphadenectomy. Overall and cancerspecific survival data were obtained from patient charts, radiographic reports, telephone contact, and a check of the Social Security Death Index. RESULTSMost tumours were transitional cell carcinoma (32, 86%), high-grade (grade III in 29, 78%) and high-stage ( ≥ pT2 in 26, 70%). Two patients had a positive surgical margin. The median (range) number of lymph nodes excised was 14 (2-24); seven patients (17%) had node-positive disease (pN1). Follow-up data were available for 35 patients (95%); eight (22%) completed ≥ 5 years of follow-up, and the mean (range) follow-up was 31 (1-66) months. At the last follow-up, 24 patients (65%) were alive with no evidence of disease and 11 (30%) were dead, two (5%) from metastasis and nine (24%) from unrelated causes. The 5-year actuarial overall, cancer-specific and recurrence-free survival was 63%, 92% and 92%, respectively. CONCLUSIONTo our knowledge, this is the first report of ≤ 5-year follow-up after LRC; the data suggest that LRC provides oncological outcomes comparable to contemporary series of open RC.

show abstract

“…On final specimen analysis (Table 2), UCC was found in 98% (495/503) of cases, while squamous cell (five of 503) and adenocarcinoma (three of 503) in 1% (Table S1). Of note, the median (interquartile range, IQR) LN retrieval was 14 (9)(10)(11)(12)(13)(14)(15)(16)(17) …”

Section: Pathological Evaluationmentioning

confidence: 99%

Long‐term analysis of oncological outcomes after laparoscopic radical cystectomy in Europe: results from a multicentre study by the European Association of Urology (EAU) section of Uro‐technology

et al. 2014

View full text Add to dashboard Cite

ObjectiveTo report long-term outcomes of laparoscopic radical cystectomy (LRC) in a multicentre European cohort, and explore feasibility and safety of LRC. Patients and MethodsThis study was coordinated by European Association of Urology (EAU)-section of Uro-technology (ESUT) with nine centres enrolling 503 patients undergoing LRC for bladder cancer prospectively between 2000 and 2013. Data were retrospectively analysed. Descriptive statistics were used to explore peri-and postoperative characteristics of th ecohort. Kaplan-Meier curves were constructed to evaluate recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS). Outcomes were also stratified according to tumour stage, lymph node (LN) involvement and surgical margin status. ResultsMinor complications (Clavien I-II) occurred in 39% and major (IIIa-IVb) in 17%. In all, 10 (2%) postoperative deaths were recorded. The median (interquartile, IQR) LN retrieval was 14 (9-17) and positive surgical margins were detected in 29 (5.8%) patients. The median (mean, IQR) follow-up was 50 (60,, during which 134 (27%) recurrences were detected. Actuarial RFS, CSS and OS rates were 66%, 75% and 62% at 5 years and 62%, 55%, 38% at 10 years. Significant differences in RFS, CSS and OS were found according to tumour stage, LN involvement and margin status (log-rank P < 0.001). On multivariate Cox analysis, T stage and LN involvement (both P < 0.001) were significant predictors of RFS, CSS and OS. Positive margins were significant predictors of RFS (P = 0.016) and CSS (P = 0.043). ConclusionsIn this European LRC multicentre study, the largest to date, long-term RFS, CSS and OS rates after LRC appear comparable to those reported in current open RC series. Further randomised controlled trials are necessary to assess the global impact of LRC.

show abstract

Laparoscopic Radical Cystoprostatectomy: Our Experience in a Consecutive Series of 10 Patients With a 3 Years Follow-Up

Cited by 11 publications

References 0 publications

Laparoscopic versus open radical cystectomy for the management of bladder cancer: Mid‐term oncological outcome

Laparoscopic versus open radical cystectomy for the management of bladder cancer: Mid‐term oncological outcome

Laparoscopic radical cystectomy for cancer: oncological outcomes at up to 5 years

Long‐term analysis of oncological outcomes after laparoscopic radical cystectomy in Europe: results from a multicentre study by the European Association of Urology (EAU) section of Uro‐technology

Contact Info

Product

Resources

About